A phase 1 clinical trial was recently performed to evaluate the feasibility and safety of FMT and reinduction of anti-PDCD1 immunotherapy in patients with anti-PDCD1 refractory metastatic melanoma. This evidence concerns the gene PDCD1 and metastatic melanoma.